Weixinkang subsidiary gets approval for inhaled acetylcysteine

Tibet Weixinkang Pharmaceutical Co., Ltd. (SSE: 603676) announced that its wholly-owned subsidiary, Yangpu Jingtai Pharmaceutical Co., Ltd., has received a drug registration certificate from the National Medical Products Administration (NMPA) for inhaled acetylcysteine solution. The drug, categorized as a Class 4 chemical drug, is indicated for respiratory conditions with excessive thick mucus. As of December 31, 2024, R&D investment in the drug totaled approximately RMB 7.08 million. The company will now prepare for the launch of the drug which is on the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2024 Edition). The market for inhaled acetylcysteine solution in China's urban and rural public hospitals reached RMB 2.573 billion in 2023 and RMB 1.127 billion in the first half of 2024.